OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥1,675 | ¥1,228 | ¥834 | ¥945 |
| Short-Term Investments | ¥0 | ¥0 | ¥0 | ¥0 |
| Receivables | ¥45 | ¥55 | ¥99 | ¥93 |
| Inventory | ¥92 | ¥112 | ¥79 | ¥70 |
| Other Curr. Assets | ¥72 | ¥76 | ¥65 | ¥46 |
| Total Curr. Assets | ¥1,886 | ¥1,481 | ¥1,106 | ¥1,182 |
| Property Plant & Equip (Net) | ¥0 | ¥0 | ¥0 | ¥0 |
| Goodwill | ¥0 | ¥0 | ¥0 | ¥0 |
| Intangibles | ¥0 | ¥0 | ¥0 | ¥0 |
| Long-Term Investments | ¥0 | ¥49 | ¥49 | ¥49 |
| Tax Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Other NC Assets | ¥50 | ¥1 | ¥1 | ¥1 |
| Total NC Assets | ¥50 | ¥50 | ¥50 | ¥50 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥1,935 | ¥1,531 | ¥1,155 | ¥1,232 |
| Liabilities | – | – | – | – |
| Payables | ¥0 | ¥0 | ¥0 | ¥0 |
| Short-Term Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Tax Payable | ¥78 | ¥0 | ¥0 | ¥0 |
| Deferred Revenue | ¥0 | ¥86 | ¥142 | ¥17 |
| Other Curr. Liab. | ¥14 | ¥241 | ¥184 | ¥163 |
| Total Curr. Liab. | ¥219 | ¥365 | ¥328 | ¥291 |
| LT Debt | ¥23 | ¥37 | ¥51 | ¥0 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Other NC Liab. | ¥47 | ¥47 | ¥47 | ¥113 |
| Total NC Liab. | ¥71 | ¥84 | ¥98 | ¥113 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liabilities | ¥289 | ¥450 | ¥426 | ¥404 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥786 | ¥382 | ¥50 | ¥647 |
| Retained Earnings | -¥27,463 | -¥27,223 | -¥26,908 | -¥26,810 |
| AOCI | ¥70 | ¥74 | ¥71 | ¥72 |
| Other Equity | -¥0 | -¥0 | -¥0 | ¥0 |
| Total Equity | ¥1,646 | ¥1,081 | ¥729 | ¥828 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥1,935 | ¥1,531 | ¥1,155 | ¥1,232 |
| Net Debt | -¥1,652 | -¥1,191 | -¥783 | -¥945 |